Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib + temozolomide as adjuvant treatment for MGMT promoter unmethylated glioblastoma
ChiCTR1900024651Phase 4Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Aug 2019
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and temozolomide in glioblastoma (GBM), sponsored by Army Specialized Medical Center. Primary endpoint: 6-month progression-free survival. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
anlotinibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR1900024651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024651.